New hope for tough prostate cancer? early trial launches
NCT ID NCT07493512
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new drug called xaluritamig (AMG 509) in 40 adults with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to hormone therapy. The main goal is to check the drug's safety and how it moves through the body. Participants receive the drug through a short IV infusion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
xaluritamig (AMG 509)
What this could lead to
If this trial succeeds, it could point toward a new treatment option for advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is a very early Phase 1b study with only 40 participants, focused mainly on safety. It is too small and early to know if the drug will work or what side effects may emerge.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Next Oncology - Dallas
RECRUITINGIrving, Texas, 75039, United States
-
Sanford Oncology Clinic and Pharmacy
RECRUITINGSioux Falls, South Dakota, 57104, United States
-
Sarah Cannon Research Institute Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States